AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06487533 — intervention group
Intervention type: DEVICE
Intervention: EmbracePlus Smartwatch
Description: The EmbracePlus is worn on the user's wrist and continuously collects raw data via specific sensors. These data can be wirelessly transmitted to a paired mobile device. The data received are analyzed by EmpaDSP, which computes the user physiological parameters. The Care App is responsible for transmitting raw data, device information, Care App-specific information, and computed physiological parameters to the Empatica Cloud. The device supports continuous data collection for monitoring of the following physiological parameters:~* Peripheral skin temperature~* Electrodermal activity~* Blood Oxygen Saturation under no motion conditions~* Activity associated with movement during sleep.~The EmbracePlus Watch has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements.
Study NCT06487533 — intervention group
Intervention type: DEVICE
Intervention: Corti Sensor
Description: The Corti Wearable is a sweat sensor that is worn continuously measure cortisol, melatonin, tumor necrosis alpha interleukin-6 (IL-6) in the protein analytes in the sweat of participants via electrochemical impedance spectroscopy. The Corti Wearable comprises a plastic reader and a replaceable polymer sweat-sensing strip with zinc oxide (ZnO) coated electrodes that is worn on the participant's forearm. It is manufactured through a screen-printing technique that allows for an affinity-based interaction between a capture probe antibody and the target molecule generating electrochemical activity.~The Cort Wearable has been used in previous human subject research studies for bio-physiological data collection in other medical conditions and have confirmed that there is minimal risk to participants. This device is therefore exempt from any IDE requirements.
Study NCT05268887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GENUS device (Active Settings)
Description: Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 30-60 minutes
Study NCT05268887 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (Sham settings)
Description: Participants in the control group will use the GENUS devices configured to the sham settings for 30-60 minutes
Study NCT03595787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaching and Habilitation
Description: nutritional support, adapted physical activity and coaching
Study NCT06396377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reborn doll (Therapeutic object - OT)
Description: If the resident is randomized to the intervention group, the investigating team will give the Reborn®doll to the resident, during a 45-minute to 1-hour workshop, twice a week for 3 weeks. The OTs, wrapped in a blanket, are presented to the residents by a member of the investigative team trained in reborning , in the resident's room. If the resident is not in his/her room, he/she will be taken back to receive his/her doll. In the case of double rooms, it will be necessary to assess whether or not to leave the room-mate in the room, in order to limit the loss of reference points for the resident concerned by the study. The caregiver lets the resident appropriate and recognize the OT, so that he or she can find meaning in it and awaken his or her sensory memory.In total, the patient will be exposed to OT 6 times.
Study NCT06261463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAFES2
Description: The adapted CAFES2 model includes an initial home visit and six multiple family group sessions delivered by peer providers. Families include at least one caregiver and one youth 12 years or older. Key model components include: 1) interfamilial discussion of stressors affecting families and family relationships, 2) psychoeducation on the effects of war and forced displacement on individuals, families and social relationships; 3) emotion regulation and self management strategies; 4) identification and activation of family and social strengths, 5) discussion of family identity and hopes for the future in resettlement and 5) discussion of social and community resources to support health and wellbeing. Each group session incorporates didactic components, family and small group discussion, skill building and separate breakout groups for adolescents and adults.
Study NCT05666375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous translumbar and transhepatic permcath
Description: For selected ESRD patients who have exhausted all conventional access routes , translumbar and transhepatic insertion of long term hemodialysis catheters provide additional sites for access
Study NCT05643963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary regimens
Description: Food intake will follow a recommendation according to a specific list. Protective and non-protective food intake will be performed for specific time periods with biomarker assessment after each period.
Study NCT04963972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in Lucid Lane therapy program
Study NCT04963972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care opioid education
Study NCT04963972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04963972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05957757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48 was scheduled to be administered at a dose of 2.0mg/kg every 2 weeks, with the first dose on day 1 of the first cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study NCT05957757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab was administered at a dose of 200 mg every 3 weeks, with the first dose on day 1 of the first 21-day cycle.~The drug is diluted with normal saline and administered by intravenous drip for one hour.
Study NCT05518422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic, euglycemic infusion
Description: 60 minute infusion
Study NCT05257759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Standard management offered in the intensive care unit
Study NCT05257759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Standard management offered in the intensive care unit
Study NCT05257759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrostimulation
Description: The patients included will receive throughout their stay, in addition to the standard care offered in the department, electrical nerve stimulation. The ES will be applied to the tibial nerve to allow contraction of the plantar flexors. The protocol will be applied twice a day, 5-7 days a week and will have the following characteristics: stimulation frequency 100Hz, pulse width 1ms, intensity allowing the development of 5-10% of the maximum tetanic force obtained during the force-frequency relation, contraction time 20s, recovery time 20s, for a total of 25 contractions per session.
Study NCT05257759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the neuromuscular system
Description: Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition.
Study NCT05257759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the neuromuscular system
Description: Will be performed within 48 hours of admission to the ICU and at D7 of admission.~Includes:~* electrical stimulations (at an intensity to obtain 10% of the maximum M wave) in the leg at different frequencies with recording of the force developed by force sensor~* maximum and submaximal electrical stimulation of the leg with recording of the electrophysiological response by surface electrodes applied to the leg muscles, to evaluate muscular and spinal excitability.~* MRC scale to assess the motor function of different muscle groups of the lower and upper of the lower and upper limbs, depending on the patient's clinical condition.~* Maximum Voluntary Contractions (MVC) to evaluate the muscular strength of the plantar flexors, depending on the patient's clinical condition.
Study NCT05717764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection
Description: Mitoxantrone hydrochloride liposome injection will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Study NCT05717764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study NCT05717764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study NCT06206122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Besides, the control group was given enteral nutritional support with Nasogastric tube according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06206122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06206122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: 1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06206122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: 1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT05369494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein infant formula with oligosaccharides
Description: Hydrolyzed protein infant formula with oligosaccharides
Study NCT06279299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral pelvic lymph node dissection
Description: Following the total mesorectal excision principle, the rectum and mesentery are removed, with careful protection of the pelvic autonomic nerves. After completing laparoscopic rectal resection, lateral lymph node dissection is performed. The lateral dissection follows these steps: ① Open the peritoneum at the bifurcation of the iliac vessels, dissect along the retroperitoneum adjacent to the ureter-bladder fascia, expose the lateral pelvic area, and carefully protect the ureter and hypogastric nerves. Open the peritoneum along the edge of the external iliac vessels close to the inguinal ligament, clear the lymphatic fatty tissue alongside the external iliac vessels along the edge of the iliopsoas and internal oblique muscles; ② After identifying the hypogastric nerve, dissect along the bladder-bladder fascia, separate the bladder and the fat tissue around the lateral pelvic space, completely remove the lymphatic tissue around the internal iliac vessels and hypogastric nerves.
Study NCT05414006 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
Study NCT05414006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine or placebo were given to the fetus after delivery Patient-controlled intravenous analgesia or patient-controlled epidural analgesia were administered postoperatively
Study NCT05438446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular ultrasound renal denervation (Paradise renal denervation system, ReCor, CA, USA) (RDN)
Description: The ReCor Medical Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark, but Investigational in the USA.~The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
Study NCT03752489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment-specific InSight
Description: The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
Study NCT03752489 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: InSight
Description: The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
Study NCT04583462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
Study NCT04583462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group : Placebo (coated tablet similar to metformin tablet titrated following the same schedule as in the experimental arm) started at 500 mg per day per os and titrated up to 2000 mg during 2 years (increase of 500 mg every two weeks)
Study NCT06002321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Patients will undergo echocardiographic examination. The ejection fraction will be calculated using Simpson's method. The E/e' ratio will be measured using the Doppler method. E/e' > 13 will be considered an expression of the increase in LVFP. TAPSE will be measured together with the peak tricuspid regurgitation velocity (TVR). Pulmonary arterial hypertension will be defined as TVR > 2.8 m/s. Estimation of right atrial pressure (eRAP) will be obtained based on the diameter and inspiratory collapsibility of the inferior vena cava.
Study NCT06002321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Test
Description: BNP, NT-proBNP and renal function.
Study NCT05037539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate 50Mcg/Ml Inj_#1
Description: Injectable Fentanyl in Sublingual Route 50 mcg
Study NCT05037539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Oral Morphine Syrup 2.5 ml ( 5 mg)
Study NCT05292482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
Study NCT05292482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions.
Study NCT04158973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge
Description: At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
Study NCT05328284 — intervention group
Intervention type: DEVICE
Intervention: PASCAL leaflet repair system
Description: transcatheter Implantation of one or more PASCAL devices in the tricuspid valve
Study NCT06241924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Electroencephalogram (EEG-HR)
Description: Local field potentials (LFP) recording using EEG-HR
Study NCT06241924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereo-electro-encephalography (SEEG)
Description: Local field potentials (LFP) recording using sEEG
Study NCT05392088 — intervention group
Intervention type: OTHER
Intervention: DATA EXTRACTION
Description: For all patients enrolled Data Mart COVID-19 developed within Generator Real World will be used to automatically extract both structured and unstructured data from hospital databases of patients infected from SARS-CoV-2.The specific data that which will be exploited are:~* Demographics data;~* Patient comorbidities, vital signs and symptoms at the time of admission;~* Laboratory analysis;~* In-hospital complications (e.g.: need for non-invasive or invasive ventilation, access to intensive care unit, length of hospitalization, use of glucocorticoids or antibiotics, death);~* Blood gas exchange information;~* Radiological reports;~* Medications at the time of admission, during hospitalization and at the time of discharge;~* Vaccination status.
Study NCT05392088 — intervention group
Intervention type: OTHER
Intervention: FOLLOW-UP
Description: All patients will undergo a clinical follow-up by telephonic interview and/or clinical visit at 12 months from hospital discharge, during which the incidence of MACE, dysrhythmias, inflammatory heart disease and/or thrombotic disorders (both as incidence of the composite and as incidence of each individual components) in the past months will be investigated.
Study NCT04936113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FB-401
Description: Topical
Study NCT05086341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: My COPD
Description: In addition to usual care, participants in the intervention group will initially meet with a physiotherapist to set up an individualized exercise program and physical activity plan. Participants will also receive a device instruction manual and a one hour of face-to-face training on how to use My COPD. The 12-week intervention is home-based, and self-managed with support from physiotherapist via My COPD. In addition to warm-up exercises, the exercise program comprises five exercises targeting major muscle groups, as well as, balance and aerobic exercise, to be conducted at least twice weekly. Via My COPD, the physiotherapists can follow activities and progress the exercise program, and the physiotherapist and the participants can contact each other. Throughout the intervention period, technical support will be available.
Study NCT06614777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsies and blood extraction
Description: Two 5 mm skin biopsies: lesional area and non-lesional area, on the trunk.~* One blood sample (20 ml) to extract the plasma.~* 15 successive tape-strippings in a lesional area.~* Scans with two swabs: lesional area (preferably the trunk, 5 cm x 5 cm area) and non-lesional area.
Study NCT06330636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: D-Allulose
Description: Test breakfast
Study NCT06330636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Saccharin
Description: placebo breakfast
Study NCT06712186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group / Group D
Description: In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.